JNJJanssen Research & Development, LLCSigning up patients
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Multiple Myeloma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 700 (planned)
- Started
- May 31, 2026
- Main results expected
- Apr 29, 2029
- Fully finished
- Dec 8, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Complete Response (CR) or Better
Measured over: Up to approximately 41 months
Progression-Free Survival (PFS)
Measured over: Up to approximately 41 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07518186 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC